Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 10
Have your own idea? Try our Stock Screener
U.S. Life Sciences Industry Analysis
UpdatedMay 11, 2025
DataAggregated Company Financials
Companies62
- 7D-3.3%
- 3M-20.7%
- 1Y-30.4%
- YTD-21.5%
Over the last 7 days, the Life Sciences industry has dropped 3.3%, driven by declines in Thermo Fisher Scientific and Danaher of 4.8% and 4.7%, respectively. In contrast, Charles River Laboratories International has gained 17%. However, the industry is down 30% over the past year. As for the next few years, earnings are expected to grow by 17% per annum.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 11 May 2025 | US$505.6b | US$142.8b | US$9.6b | 34.4x | 52.7x | 3.5x |
| Tue, 08 Apr 2025 | US$509.0b | US$142.5b | US$9.9b | 33.1x | 51.2x | 3.6x |
| Thu, 06 Mar 2025 | US$590.9b | US$143.0b | US$9.7b | 40.3x | 60.6x | 4.1x |
| Sat, 01 Feb 2025 | US$695.8b | US$143.0b | US$10.4b | 41.1x | 66.9x | 4.9x |
| Mon, 30 Dec 2024 | US$657.8b | US$142.4b | US$10.2b | 44.7x | 64.3x | 4.6x |
| Wed, 27 Nov 2024 | US$663.1b | US$142.4b | US$10.2b | 44.5x | 64.8x | 4.7x |
| Fri, 25 Oct 2024 | US$701.1b | US$142.0b | US$8.3b | 34.8x | 84.3x | 4.9x |
| Sun, 22 Sep 2024 | US$746.6b | US$141.8b | US$8.5b | 37.7x | 87.9x | 5.3x |
| Tue, 20 Aug 2024 | US$738.9b | US$141.9b | US$8.3b | 38.9x | 89.1x | 5.2x |
| Thu, 18 Jul 2024 | US$704.4b | US$141.2b | US$12.2b | 40.4x | 57.7x | 5x |
| Sat, 15 Jun 2024 | US$698.2b | US$141.3b | US$12.2b | 37.1x | 57.3x | 4.9x |
| Mon, 13 May 2024 | US$729.1b | US$141.5b | US$12.6b | 38.6x | 57.6x | 5.2x |
| Wed, 10 Apr 2024 | US$729.8b | US$142.1b | US$12.8b | 44x | 57x | 5.1x |
| Fri, 08 Mar 2024 | US$757.1b | US$142.1b | US$12.8b | 44.7x | 59x | 5.3x |
| Sun, 04 Feb 2024 | US$709.3b | US$147.5b | US$12.5b | 38.3x | 56.6x | 4.8x |
| Tue, 02 Jan 2024 | US$700.2b | US$153.8b | US$14.2b | 37.8x | 49.2x | 4.6x |
| Thu, 30 Nov 2023 | US$634.5b | US$153.8b | US$14.0b | 35x | 45.3x | 4.1x |
| Sat, 28 Oct 2023 | US$565.9b | US$153.8b | US$11.3b | 29.2x | 50.3x | 3.7x |
| Mon, 25 Sep 2023 | US$670.2b | US$154.6b | US$11.2b | 33.5x | 59.8x | 4.3x |
| Wed, 23 Aug 2023 | US$699.5b | US$154.6b | US$11.2b | 32.8x | 62.4x | 4.5x |
| Fri, 21 Jul 2023 | US$716.9b | US$155.5b | US$12.7b | 29.5x | 56.5x | 4.6x |
| Sun, 18 Jun 2023 | US$704.2b | US$152.4b | US$12.5b | 29.3x | 56.3x | 4.6x |
| Tue, 16 May 2023 | US$677.1b | US$152.4b | US$12.6b | 28.6x | 53.6x | 4.4x |
| Thu, 13 Apr 2023 | US$729.2b | US$154.6b | US$10.8b | 30.1x | 67.5x | 4.7x |
| Sat, 11 Mar 2023 | US$693.6b | US$154.5b | US$10.9b | 29.6x | 63.9x | 4.5x |
| Mon, 06 Feb 2023 | US$773.1b | US$155.7b | US$9.1b | 32x | 84.9x | 5x |
| Wed, 04 Jan 2023 | US$722.5b | US$155.2b | US$8.8b | 28.6x | 82.3x | 4.7x |
| Fri, 02 Dec 2022 | US$784.4b | US$155.1b | US$8.8b | 29.2x | 89.4x | 5.1x |
| Sun, 30 Oct 2022 | US$720.5b | US$154.5b | US$13.0b | 27x | 55.6x | 4.7x |
| Tue, 27 Sep 2022 | US$705.4b | US$152.2b | US$17.3b | 25.3x | 40.8x | 4.6x |
| Thu, 25 Aug 2022 | US$798.3b | US$152.3b | US$17.3b | 30.4x | 46.1x | 5.2x |
| Sat, 23 Jul 2022 | US$803.1b | US$148.1b | US$20.1b | 32.7x | 40x | 5.4x |
| Mon, 20 Jun 2022 | US$674.6b | US$148.1b | US$20.1b | 27.5x | 33.6x | 4.6x |
| Wed, 18 May 2022 | US$722.0b | US$148.0b | US$20.1b | 30.7x | 36x | 4.9x |
Price to Earnings Ratio
36x
Current Industry PE
- Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 52.7x which is lower than its 3-year average PE of 60.5x.
- The 3-year average PS ratio of 4.7x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 22% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.26% | |
| Healthcare | -4.28% | |
| Life Sciences | -3.35% | |
| Clinical Research and Equipment | -3.35% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CRL Charles River Laboratories International | US$138.79 | 17.2% +US$998.5m | -39.2% | PS1.7x | |
| TEM Tempus AI | US$61.37 | 7.6% +US$750.9m | n/a | PS13.2x | |
| STVN Stevanato Group | US$24.00 | 12.3% +US$715.0m | 10.0% | PE46.4x | |
| SHC Sotera Health | US$13.13 | 6.1% +US$212.9m | 18.9% | PE150.4x | |
| WST West Pharmaceutical Services | US$213.06 | 0.8% +US$127.2m | -41.5% | PE32.8x |
